Your browser doesn't support javascript.
loading
Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors.
Kondo, Tomohiro; Kikuchi, Osamu; Yamamoto, Yoshihiro; Sunami, Tomohiko; Wang, Yafeng; Fukuyama, Keita; Saito, Tomoki; Nakahara, Hideto; Minamiguchi, Sachiko; Kanai, Masashi; Sueyoshi, Atsushi; Muto, Manabu.
Afiliación
  • Kondo T; Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kikuchi O; Japan Society for the Promotion of Science, Tokyo, Japan.
  • Yamamoto Y; Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Sunami T; Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Wang Y; Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Fukuyama K; Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Saito T; Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, Kyoto, Japan.
  • Nakahara H; Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Minamiguchi S; Department of Surgery, Uji Tokushukai Medical Center, Uji, Japan.
  • Kanai M; Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
  • Sueyoshi A; Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Muto M; Uji-Tokushukai Medical Center, Uji, Japan.
Oncologist ; 2024 May 31.
Article en En | MEDLINE | ID: mdl-38821532
ABSTRACT
Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare, recurrent oncogenic variant that constitutively activates EGFR in non-small-cell lung cancer. Herein, we report the case of a 70-year-old man with resectable colorectal adenocarcinoma who underwent surgery followed by adjuvant therapy. He relapsed with multiple liver metastases and received standard chemotherapy until his disease became refractory. Comprehensive genomic profiling of his postoperative colorectal cancer tissue revealed EGFR-KDD. He was treated with an EGFR tyrosine kinase inhibitor (TKI), afatinib and achieved a partial response (- 55%) after 8 weeks; however, he developed massive malignant ascites after 13 weeks. Osimertinib, another EGFR-TKI, controlled his tumors for 9 months. Patient-derived cancer organoids from his malignant ascites confirmed sensitivity to EGFR-TKIs. The findings suggest that EGFR-TKIs can be a potential treatment option for this molecular subgroup.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido